(New Follow-up) Potential use of ozone in SARS-CoV-2 / COVID-19.

International Scientific Committee of Ozone Therapy ISCO3. ISCO3/EPI/00/04.

Original drafters of the paper: Adriana Schwartz, Scientific Secretary of ISCO3, Gregorio Martínez-Sánchez, President of ISCO3.

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue. The COVID-19 has been characterized as a “pandemic” by the World Health Organization (WHO). The most official recent and available data on March 12th, 2020 has shown that almost 125,000 cases have now been reported to WHO, from 118 countries and territories. In the past two weeks, the number of cases reported outside China has increased almost 13-fold, and the number of affected countries has almost tripled.3 “4,291 people have lost their lives (…) in the days and weeks ahead, we expect to see the number of cases, the number of deaths, and the number of affected countries climb even higher.”2 The scope of this paper is to review “the potential ozone utilization that serves as a complementary therapy” in the management of COVID-19. Evidence acquisition terms (ozone, SARS-CoV-2 and COVID-19) was searched in the scientific data bases.

Read the whole report in PDF:


FOLLOW-UP to the clinical protocol to study the effect of ozone in SARS-CoV-2 / COVID-19 © ISCO3. 2020
Follow-up to the preliminary results about use of sistemic of O2/O3 in the treatment of Novel Coronavirus Pneumonia (COVID-19):